Lexicon Pharmaceuticals | LXRX - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
Abbott USD 2.36B 178M 2025-12
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Akebia Therapeutics USD -11.24M 12.39M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
AstraZeneca USD 3.24B 117M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Esperion Therapeutics USD 63.67M 95M 2025-12
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Illumina USD 220M 86M 2025-09
Insmed USD -326.93M 41.77M 2025-12
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
J&J USD 4.97B 2.53B 2025-12
Lexicon Pharmaceuticals USD -12.77M 16.02M 2025-09
MacroGenics USD -14.93M 31.75M 2025-12
MannKind USD -20.93M 28.71M 2025-12
Merck USD 6.74B 22M 2025-09
Moderna USD -187M 631M 2025-09
Novartis USD 4.64B 445M 2025-12
PTC Therapeutics USD -139.08M 116.01M 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Thermo Fisher Scientific USD 2.12B 295M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
United Therapeutics USD 444M 6M 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12